Author

A. Van Den Abbeele

Observed names: A Van den Abbeele, A. van den Abbeele, AD Van den Abbeele

Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Observed institutions: University of North Carolina at Chapel Hill, Brigham and Women's Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, Pfizer (United States), Baylor College of Medicine, Vanderbilt University, University of Alabama at Birmingham, University of Chicago, Infinity Pharmaceuticals (United States), Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Vanderbilt-Ingram Cancer Center, University of California, Davis

OpenAlex ID: A5110310090

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)

2004 · G. D. Demetri, J. Desai, et al. · Journal of Clinical Oncology · 107

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy

2009 · D.J. Sher, P.M. Mauch, et al. · Annals of Oncology · 90

Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM)

2004 · P. Dileo, R. Randhawa, et al. · Journal of Clinical Oncology · 37

Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial

2007 · G. D. Demetri, S. George, et al. · Journal of Clinical Oncology · 25

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST)

2005 · A. van den Abbeele, Y. Melenevsky, et al. · Journal of Clinical Oncology · 23

570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor

2006 · G.D. Demetri, S. George, et al. · European Journal of Cancer Supplements · 8

383 POSTER A Phase I Study of dasatinib, a Src and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors

2006 · J. Morgan, G. Demetri, et al. · European Journal of Cancer Supplements · 5

O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy

2005 · R. Herbst, A. Davies, et al. · Lung Cancer · 5

Primary cardiac angiosarcoma presenting as a malignant pericardial effusion.

1998 · C Wu, M Vasconcelles, et al. · Journal of Clinical Oncology · 4

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST)

2006 · C. P. Raut, A. Van Den Abbeele, et al. · Journal of Clinical Oncology · 3

Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy

2017 · HA Jacene, B Overmoyer, et al. · Cancer Research

P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003.

2011 · JT Yap, T Locascio, et al. · Cancer Research

Works count: 12

Citation count: 307

H-index: 6

I10-index: 5